Rx Medicare

China Sky One Medical, Inc. (“China Sky One Medical” or “the Company”) (Nasdaq: CSKI), a leading fully integrated pharmaceutical company producing over-the-counter drugs in the People’s Republic of China (“PRC”), announced that it obtained approvals from the State Food and Drug Administration (SFDA) in China for the production of Geranium ointment and Musk liniment for pain relief. Geranium ointment is used to cure chronic eczema, carbuncle, furuncle and small scalds.

Read More…

Related Posts

• Multi-Center Data In A Large Series Of Patients Show Vertebroplasty Provides Dramatic And Lasting Pain Relief For Vertebral Compression Fractures
• Clinical Trial: Miniature Ultrasound Device Could Revolutionize Pain Relief
• FDA Approves Morphine Sulfate Oral Solution For Relief Of Acute And Chronic Pain
• Officials Debate Merits Of Medical Marijuana As Coping Tool In Pain Fight
• Innovative Medical Equipment Launches Sootheaway Device For Migraine Relief
• China Aoxing Pharmaceutical Company Announces Successful Completion Of Phase II Clinical Study Of Novel Menstrual Pain Drug
• Outpatient disc treatment gives long-term back pain relief
• A Cup Of Brazilian Mint For Pain Relief
• 62-Year-Old Man Becomes First Patient In China Implanted With Rechargeable Neurostimulator For Chronic Pain
• Common pain relief medication may encourage cancer growth
• FDA Approves New Drug Treatment For Long-Term Pain Relief After Shingles Attacks
• Cancer, Pain Relief And Immunity Research Supported By ARC
• 100-Year-Old Woman Gets Relief From Debilitating Back Pain After Minimally Invasive Spine Surgery
• Pacira’s Phase III Study Of EXPAREL(TM) Meets Primary Pain Relief Endpoint
• Newly Published Clinical Data Shows Caldolor(R) (Ibuprofen) Injection Reduces Opioid Use While Improving Pain Relief In Post-Operative Patients

Tags: approvals, china, geranium, liniment, medical, musk, obtains, ointment, pain, relief, sfda

This entry was posted on Friday, April 24th, 2009 at 10:04 pm and is filed under Analgesics Pain Migraine. You can follow any responses to this entry through the RSS 2.0 feed. Both comments and pings are currently closed.